UNSPSC 51392224: Lofexidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V47G1SDI1B, chemically known as 2-imidazoline, 2-(1-(2,6-dichlorophenoxy)ethyl)-, monohydrochloride but more generally known as lofexidine hydrochloride, which bears US NIH Compound Identifier 30667. European Medicines Agency schedules Lofexidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02966MIG.

Most nations, for tariff and trade purposes, schedule lofexidine hydrochloride under HS 29332990. As of Q4 2014, LOFEXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lofexidine hydrochloride bears US NLM identifiers UMLS ID C0771049 and NCI Concept Code C87581. SMILES: CC(C1=NCCN1)OC2C(CCCC2CL)CL.CL.

UNSPSC 51392224 Lofexidine hydrochloride is a Commodity code tracking pharmaceutical products used in opioid use disorder treatment and substance-abuse interventions within state and local health systems. However, the single recent state-local opportunity tagged under this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—involves naloxone procurement rather than lofexidine, indicating a mismatch between the code's nominal scope and the work actually being solicited. The opportunity solicits approximately 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries required to the Seminole County Community Health Building. Vendors must submit bids electronically, include all shipping and delivery costs in pricing, maintain workers' compensation and commercial general liability insurance, comply with E-Verify requirements and drug-free workplace certification, and accept a three-month probationary termination clause. The contract structure includes an initial two-year term with an optional one-year renewal and is potentially FEMA-funded, subjecting bidders to federal compliance obligations including adherence to the Clean Air Act and Federal Water Pollution Control Act.

The code shows minimal recent activity with only this single identified opportunity. Seminole County, Florida represents the only issuing body surfaced in the recent-opportunities block, and the geographic scope is therefore limited to Florida. The Seminole County IFB (IFB60459723LAS) posted on June 30, 2026, with a response deadline of July 26, 2023—a date that appears inconsistent with the posting date and may indicate a data entry error in the source. The mismatch between the code's stated pharmaceutical scope (lofexidine) and the actual solicitation (naloxone and drug deactivation systems) suggests this code may not be actively used by state and local procurement offices for substantive pharmaceutical contracting, or that tagging accuracy is unreliable under this commodity classification.